PFE Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-03-14 | 2021 | M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development | 1,478,750 | 0 | 2,531,393 | 3,250,000 | 0 | 7,260,143 |
| 2024-03-14 | 2022 | M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development | 1,535,000 | 0 | 3,471,267 | 3,530,972 | 0 | 8,537,239 |
| 2024-03-14 | 2021 | A. Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business | 1,220,000 | 0 | 1,975,798 | 2,984,700 | 0 | 9,032,934 |
| 2024-03-14 | 2023 | A. Bourla Chairman and Chief Executive Officer | 1,787,500 | 0 | 8,745,187 | 0 | 0 | 10,532,687 |
| 2024-03-14 | 2022 | A. Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business | 1,276,500 | 0 | 2,661,590 | 2,936,438 | 0 | 9,746,368 |
| 2024-03-14 | 2023 | A. Hwang Former Chief Commercial Officer and President, Global Biopharmaceuticals Business | 1,340,450 | 0 | 2,336,483 | 0 | 0 | 6,693,779 |
| 2024-03-14 | 2023 | A. Malik Chief U.S. Commercial Officer, EVP | 1,294,800 | 0 | 1,336,257 | 0 | 0 | 2,631,057 |
| 2024-03-14 | 2022 | W. Pao Former Chief Development Officer, EVP | 937,500 | 5,000,000 | 5,999,988 | 1,565,557 | 0 | 13,503,045 |
| 2024-03-14 | 2023 | W. Pao Former Chief Development Officer, EVP | 772,500 | 691,939 | 577,860 | 0 | 2,505,158 | 6,251,118 |
| 2024-03-14 | 2022 | A. Bourla Chairman and Chief Executive Officer | 1,737,500 | 0 | 9,296,191 | 7,650,000 | 0 | 18,683,691 |
| 2024-03-14 | 2023 | D. Denton Chief Financial Officer, EVP | 1,296,875 | 0 | 1,341,079 | 0 | 0 | 2,637,954 |
| 2024-03-14 | 2023 | M. Dolsten Chief Scientific Officer, President, Pfizer Research & Development | 1,596,500 | 0 | 3,115,268 | 0 | 0 | 4,711,768 |
| 2024-03-14 | 2022 | D. Denton Chief Financial Officer, EVP | 833,333 | 5,000,000 | 4,000,012 | 1,838,355 | 0 | 11,671,700 |
| 2024-03-14 | 2021 | A. Bourla Chairman and Chief Executive Officer | 1,687,500 | 0 | 6,180,808 | 8,000,000 | 0 | 15,868,308 |
| 2024-03-14 | 2021 | D. Lankler General Counsel, EVP | 1,102,500 | 0 | 1,587,984 | 2,191,860 | 0 | 4,882,344 |
| 2024-03-14 | 2022 | D. Lankler General Counsel, EVP | 1,143,750 | 0 | 2,160,626 | 2,264,931 | 0 | 5,569,307 |
| 2024-03-14 | 2023 | D. Lankler General Counsel, EVP | 1,198,313 | 0 | 1,817,208 | 0 | 0 | 3,015,521 |
| 2023-03-16 | 2022 | F. D’Amelio Former Chief Financial Officer, EVP | 1,448,333 | 0 | 3,703,779 | 1,445,808 | 0 | 10,538,666 |
| 2023-03-16 | 2021 | F. D’Amelio Former Chief Financial Officer, EVP | 1,571,250 | 0 | 2,840,271 | 2,925,000 | 0 | 7,336,521 |
| 2023-03-16 | 2020 | A. Bourla Chairman and Chief Executive Officer | 1,650,000 | 0 | 4,897,817 | 5,491,800 | 0 | 12,039,617 |
| 2023-03-16 | 2022 | D. Denton Chief Financial Officer, EVP | 833,333 | 5,000,000 | 4,000,012 | 1,838,355 | 0 | 11,671,700 |
| 2023-03-16 | 2021 | A. Bourla Chairman and Chief Executive Officer | 1,687,500 | 0 | 6,180,808 | 8,000,000 | 0 | 15,868,308 |
| 2023-03-16 | 2022 | A. Bourla Chairman and Chief Executive Officer | 1,737,500 | 0 | 9,296,191 | 7,650,000 | 0 | 18,683,691 |
| 2023-03-16 | 2022 | W. Pao Chief Development Officer, EVP | 937,500 | 5,000,000 | 5,999,988 | 1,565,557 | 0 | 13,503,045 |
| 2023-03-16 | 2022 | M. Dolsten Chief Scientific Officer and President, Worldwide Research, Development and Medical | 1,535,000 | 0 | 3,471,267 | 3,530,972 | 0 | 8,537,239 |
| 2023-03-16 | 2021 | M. Dolsten Chief Scientific Officer and President, Worldwide Research, Development and Medical | 1,478,750 | 0 | 2,531,393 | 3,250,000 | 0 | 7,260,143 |
| 2023-03-16 | 2020 | M. Dolsten Chief Scientific Officer and President, Worldwide Research, Development and Medical | 1,433,750 | 0 | 2,110,585 | 2,600,000 | 0 | 6,144,335 |
| 2023-03-16 | 2022 | A. Hwang Chief Commercial Officer and President, Global Biopharmaceuticals Business | 1,276,500 | 0 | 2,661,590 | 2,936,438 | 0 | 9,746,368 |
| 2023-03-16 | 2021 | A. Hwang Chief Commercial Officer and President, Global Biopharmaceuticals Business | 1,220,000 | 0 | 1,975,798 | 2,984,700 | 0 | 9,032,934 |
| 2023-03-16 | 2020 | A. Hwang Chief Commercial Officer and President, Global Biopharmaceuticals Business | 1,142,500 | 0 | 1,420,129 | 2,387,800 | 0 | 7,883,447 |
| 2023-03-16 | 2020 | F. D’Amelio Former Chief Financial Officer, EVP | 1,533,750 | 0 | 2,406,437 | 2,470,000 | 517,016 | 6,927,203 |
| 2022-03-17 | 2021 | D. Lankler General Counsel, EVP | 1,102,500 | 0 | 1,587,984 | 2,191,860 | 0 | 7,129,372 |
| 2022-03-17 | 2019 | F. D’Amelio Chief Financial Officer, EVP, Global Supply | 1,500,000 | 0 | 2,582,446 | 1,820,000 | 523,472 | 11,075,730 |
| 2022-03-17 | 2021 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,478,750 | 0 | 2,531,393 | 3,250,000 | 0 | 10,914,990 |
| 2022-03-17 | 2020 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,433,750 | 0 | 2,110,585 | 2,600,000 | 467,819 | 10,149,624 |
| 2022-03-17 | 2019 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,400,000 | 0 | 2,414,725 | 1,820,000 | 444,701 | 9,598,045 |
| 2022-03-17 | 2021 | A. Hwang Group President, Pfizer Biopharmaceuticals Group | 1,220,000 | 0 | 1,975,798 | 2,984,700 | 0 | 9,032,934 |
| 2022-03-17 | 2021 | A. Bourla Chairman and Chief Executive Officer | 1,687,500 | 0 | 6,180,808 | 8,000,000 | 0 | 15,868,308 |
| 2022-03-17 | 2020 | A. Bourla Chairman and Chief Executive Officer | 1,650,000 | 0 | 4,897,817 | 5,491,800 | 0 | 12,039,617 |
| 2022-03-17 | 2019 | A. Bourla Chairman and Chief Executive Officer | 1,600,000 | 0 | 4,290,956 | 3,630,000 | 606,269 | 17,928,963 |
| 2022-03-17 | 2021 | F. D’Amelio Chief Financial Officer, EVP, Global Supply | 1,571,250 | 0 | 2,840,271 | 2,925,000 | 0 | 7,336,521 |
| 2022-03-17 | 2020 | F. D’Amelio Chief Financial Officer, EVP, Global Supply | 1,533,750 | 0 | 2,406,437 | 2,470,000 | 517,016 | 6,927,203 |
| 2022-03-17 | 2020 | J. Young Former Group President, Chief Business Officer | 1,285,000 | 0 | 1,814,734 | 1,800,000 | 450,994 | 8,989,193 |
| 2022-03-17 | 2021 | J. Young Former Group President, Chief Business Officer | 1,322,750 | 0 | 1,893,548 | 2,387,800 | 0 | 8,332,681 |
| 2022-03-17 | 2020 | A. Hwang Group President, Pfizer Biopharmaceuticals Group | 1,142,500 | 0 | 1,420,129 | 2,387,800 | 440,714 | 7,883,447 |
| 2022-03-17 | 2019 | J. Young Former Group President, Chief Business Officer | 1,245,000 | 0 | 2,247,004 | 1,675,000 | 441,439 | 8,959,383 |
| 2021-03-12 | 2019 | J. Young Chief Business Officer, Group President | 1,245,000 | 0 | 2,247,004 | 1,675,000 | 441,439 | 8,959,383 |
| 2021-03-12 | 2018 | J. Young Chief Business Officer, Group President | 1,206,250 | 0 | 2,013,091 | 1,385,000 | 408,379 | 7,121,715 |
| 2021-03-12 | 2020 | A. Bourla Chairman and Chief Executive Officer | 1,650,000 | 0 | 4,897,817 | 5,491,800 | 0 | 12,039,617 |
| 2021-03-12 | 2019 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,400,000 | 0 | 2,414,725 | 1,820,000 | 444,701 | 9,598,045 |
| 2021-03-12 | 2020 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,433,750 | 0 | 2,110,585 | 2,600,000 | 467,819 | 10,149,624 |
| 2021-03-12 | 2018 | F. D’Amelio Chief Financial Officer and EVP, Global Supply | 1,407,917 | 0 | 2,013,091 | 1,310,000 | 299,826 | 7,139,829 |
| 2021-03-12 | 2019 | F. D’Amelio Chief Financial Officer and EVP, Global Supply | 1,500,000 | 0 | 2,582,446 | 1,820,000 | 523,472 | 11,075,730 |
| 2021-03-12 | 2020 | F. D’Amelio Chief Financial Officer and EVP, Global Supply | 1,533,750 | 0 | 2,406,437 | 2,470,000 | 517,016 | 6,927,203 |
| 2021-03-12 | 2019 | A. Bourla Chairman and Chief Executive Officer | 1,600,000 | 0 | 4,290,956 | 3,630,000 | 606,269 | 17,928,963 |
| 2021-03-12 | 2018 | A. Bourla Chairman and Chief Executive Officer | 1,400,000 | 0 | 2,592,079 | 1,533,000 | 375,109 | 9,854,557 |
| 2021-03-12 | 2018 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,306,250 | 0 | 2,013,091 | 1,326,000 | 315,863 | 7,070,199 |
| 2021-03-12 | 2020 | A. Hwang Group President, Pfizer Biopharmaceuticals Group | 1,142,500 | 0 | 1,420,129 | 2,387,800 | 440,714 | 7,883,447 |
| 2021-03-12 | 2020 | J. Young Chief Business Officer, Group President | 1,285,000 | 0 | 1,814,734 | 1,800,000 | 450,994 | 8,989,193 |
| 2020-03-13 | 2019 | A. Bourla Chief Executive Officer | 1,600,000 | 0 | 4,290,956 | 3,630,000 | 606,269 | 17,928,963 |
| 2020-03-13 | 2018 | J. Young Chief Business Officer, Group President | 1,206,250 | 0 | 2,013,091 | 1,385,000 | 408,379 | 7,121,715 |
| 2020-03-13 | 2017 | J. Young Chief Business Officer, Group President | 1,170,000 | 0 | 3,882,186 | 1,015,000 | 481,210 | 11,506,110 |
| 2020-03-13 | 2019 | J. Young Chief Business Officer, Group President | 1,245,000 | 0 | 2,247,004 | 1,675,000 | 441,439 | 8,959,383 |
| 2020-03-13 | 2017 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,271,250 | 0 | 1,882,190 | 1,150,000 | 233,351 | 7,670,815 |
| 2020-03-13 | 2018 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,306,250 | 0 | 2,013,091 | 1,326,000 | 315,863 | 7,070,199 |
| 2020-03-13 | 2019 | M. Dolsten Chief Scientific Officer, President, Worldwide Research, Development and Medical | 1,400,000 | 0 | 2,414,725 | 1,820,000 | 444,701 | 9,598,045 |
| 2020-03-13 | 2017 | F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply | 1,356,750 | 0 | 1,882,190 | 1,120,000 | 190,740 | 8,298,034 |
| 2020-03-13 | 2018 | F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply | 1,407,917 | 0 | 2,013,091 | 1,310,000 | 299,826 | 7,139,829 |
| 2020-03-13 | 2019 | F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply | 1,500,000 | 0 | 2,582,446 | 1,820,000 | 523,472 | 11,075,730 |
| 2020-03-13 | 2017 | I. Read Executive Chairman | 1,956,750 | 0 | 6,631,652 | 2,600,000 | 472,359 | 27,913,775 |
| 2020-03-13 | 2018 | I. Read Executive Chairman | 1,992,500 | 0 | 7,030,630 | 3,000,000 | 671,846 | 19,549,213 |
| 2020-03-13 | 2019 | I. Read Executive Chairman | 1,200,000 | 0 | 6,743,656 | 2,520,000 | 788,355 | 16,286,465 |
| 2020-03-13 | 2017 | A. Bourla Chief Executive Officer | 1,170,000 | 0 | 1,651,093 | 1,260,000 | 186,324 | 8,836,301 |
| 2020-03-13 | 2018 | A. Bourla Chief Executive Officer | 1,400,000 | 0 | 2,592,079 | 1,533,000 | 375,109 | 9,854,557 |
| 2019-03-14 | 2018 | F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply | 1,407,917 | 0 | 2,013,091 | 1,310,000 | 299,826 | 7,139,829 |
| 2019-03-14 | 2017 | F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply | 1,356,750 | 0 | 1,882,190 | 1,120,000 | 190,740 | 8,298,034 |
| 2019-03-14 | 2016 | F. D’Amelio Chief Financial Officer, EVP, Business Operations and Global Supply | 1,324,000 | 0 | 1,144,494 | 1,740,000 | 180,956 | 7,694,353 |
| 2019-03-14 | 2018 | A. Bourla Chief Operating Officer | 1,400,000 | 0 | 2,592,079 | 1,533,000 | 375,109 | 9,854,557 |
| 2019-03-14 | 2018 | J. Young Group President, Pfizer Innovative Health | 1,206,250 | 0 | 2,013,091 | 1,385,000 | 408,379 | 7,121,715 |
| 2019-03-14 | 2017 | J. Young Group President, Pfizer Innovative Health | 1,170,000 | 0 | 3,882,186 | 1,015,000 | 481,210 | 11,506,110 |
| 2019-03-14 | 2016 | J. Young Group President, Pfizer Innovative Health | 1,130,000 | 0 | 1,144,494 | 1,788,000 | 1,497,688 | 7,395,741 |
| 2019-03-14 | 2016 | A. Bourla Chief Operating Officer | 1,117,500 | 0 | 936,941 | 1,788,000 | 1,169,333 | 8,870,445 |
| 2019-03-14 | 2018 | M. Dolsten President, Worldwide Research and Development | 1,306,250 | 0 | 2,013,091 | 1,326,000 | 315,863 | 7,070,199 |
| 2019-03-14 | 2017 | M. Dolsten President, Worldwide Research and Development | 1,271,250 | 0 | 1,882,190 | 1,150,000 | 233,351 | 7,670,815 |
| 2019-03-14 | 2016 | M. Dolsten President, Worldwide Research and Development | 1,237,500 | 0 | 1,144,494 | 1,740,000 | 1,226,758 | 8,227,973 |
| 2019-03-14 | 2017 | A. Bourla Chief Operating Officer | 1,170,000 | 0 | 1,651,093 | 1,260,000 | 186,324 | 8,836,301 |
| 2019-03-14 | 2018 | I. Read Chairman and Chief Executive Officer | 1,992,500 | 0 | 7,030,630 | 3,000,000 | 671,846 | 19,549,213 |
| 2019-03-14 | 2017 | I. Read Chairman and Chief Executive Officer | 1,956,750 | 0 | 6,631,652 | 2,600,000 | 472,359 | 27,913,775 |
| 2019-03-14 | 2016 | I. Read Chairman and Chief Executive Officer | 1,905,250 | 0 | 3,984,592 | 4,000,000 | 471,510 | 17,321,470 |
| 2018-03-15 | 2016 | J. Young Group President, Pfizer Essential Health | 1,130,000 | 0 | 1,144,494 | 1,788,000 | 1,497,688 | 7,395,741 |
| 2018-03-15 | 2017 | J. Young Group President, Pfizer Essential Health | 1,170,000 | 0 | 3,882,186 | 1,015,000 | 481,210 | 11,506,110 |
| 2018-03-15 | 2016 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,324,000 | 0 | 1,144,494 | 1,740,000 | 180,956 | 7,694,353 |
| 2018-03-15 | 2015 | I. Read Chairman and Chief Executive Officer | 1,858,750 | 0 | 2,011,628 | 4,300,000 | 388,036 | 17,987,962 |
| 2018-03-15 | 2015 | M. Dolsten President, Worldwide Research and Development | 1,207,500 | 0 | 603,492 | 1,850,000 | 185,813 | 6,057,866 |
| 2018-03-15 | 2017 | M. Dolsten President, Worldwide Research and Development | 1,271,250 | 0 | 1,882,190 | 1,150,000 | 233,351 | 7,670,815 |
| 2018-03-15 | 2017 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,356,750 | 0 | 1,882,190 | 1,120,000 | 190,740 | 8,298,034 |
| 2018-03-15 | 2016 | M. Dolsten President, Worldwide Research and Development | 1,237,500 | 0 | 1,144,494 | 1,740,000 | 1,226,758 | 8,227,973 |
| 2018-03-15 | 2017 | I. Read Chairman and Chief Executive Officer | 1,956,750 | 0 | 6,631,652 | 2,600,000 | 472,359 | 27,913,775 |
| 2018-03-15 | 2016 | I. Read Chairman and Chief Executive Officer | 1,905,250 | 0 | 3,984,592 | 4,000,000 | 471,510 | 17,321,470 |
| 2018-03-15 | 2015 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,293,750 | 0 | 603,492 | 2,341,000 | 169,132 | 6,670,174 |
| 2018-03-15 | 2016 | A. Bourla Group President, Pfizer Innovative Health | 1,117,500 | 0 | 936,941 | 1,788,000 | 1,169,333 | 8,870,445 |
| 2018-03-15 | 2017 | A. Bourla Group President, Pfizer Innovative Health | 1,170,000 | 0 | 1,651,093 | 1,260,000 | 186,324 | 8,836,301 |
| 2018-03-15 | 2015 | J. Young Group President, Pfizer Essential Health | 1,085,000 | 0 | 603,492 | 2,100,000 | 377,537 | 5,918,925 |
| 2017-03-16 | 2015 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,293,750 | 0 | 603,492 | 2,341,000 | 169,132 | 6,670,174 |
| 2017-03-16 | 2014 | I. Read Chairman and Chief Executive Officer | 1,815,000 | 0 | 6,447,998 | 3,000,000 | 391,828 | 23,283,048 |
| 2017-03-16 | 2016 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,324,000 | 0 | 1,144,494 | 1,740,000 | 180,956 | 7,694,353 |
| 2017-03-16 | 2015 | I. Read Chairman and Chief Executive Officer | 1,858,750 | 0 | 2,011,628 | 4,300,000 | 388,036 | 17,987,962 |
| 2017-03-16 | 2016 | I. Read Chairman and Chief Executive Officer | 1,905,250 | 0 | 3,984,592 | 4,000,000 | 471,510 | 17,321,470 |
| 2017-03-16 | 2014 | G. Germano Former Group President, Global Innovative Pharma Business | 1,150,000 | 0 | 1,813,518 | 1,355,000 | 630,593 | 9,555,852 |
| 2017-03-16 | 2015 | G. Germano Former Group President, Global Innovative Pharma Business | 1,168,750 | 0 | 603,492 | 1,850,000 | 187,621 | 6,782,720 |
| 2017-03-16 | 2016 | G. Germano Former Group President, Global Innovative Pharma Business | 489,583 | 0 | 533,704 | 486,109 | 5,485,304 | 13,216,011 |
| 2017-03-16 | 2014 | J. Young Group President, Pfizer Essential Health | 1,040,000 | 0 | 1,813,518 | 1,260,000 | 326,498 | 7,250,187 |
| 2017-03-16 | 2015 | J. Young Group President, Pfizer Essential Health | 1,085,000 | 0 | 603,492 | 2,100,000 | 377,537 | 5,918,925 |
| 2017-03-16 | 2016 | J. Young Group President, Pfizer Essential Health | 1,130,000 | 0 | 1,144,494 | 1,788,000 | 1,497,688 | 7,395,741 |
| 2017-03-16 | 2014 | M. Dolsten President, Worldwide Research and Development | 1,177,500 | 0 | 1,863,860 | 1,300,000 | 156,180 | 7,275,054 |
| 2017-03-16 | 2015 | M. Dolsten President, Worldwide Research and Development | 1,207,500 | 0 | 603,492 | 1,850,000 | 185,813 | 6,057,866 |
| 2017-03-16 | 2016 | M. Dolsten President, Worldwide Research and Development | 1,237,500 | 0 | 1,144,494 | 1,740,000 | 1,226,758 | 8,227,973 |
| 2017-03-16 | 2016 | A. Bourla Group President, Pfizer Innovative Health | 1,117,500 | 0 | 936,941 | 1,788,000 | 1,169,333 | 8,870,445 |
| 2017-03-16 | 2014 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,268,750 | 0 | 2,140,974 | 1,300,000 | 217,488 | 8,482,813 |
| 2016-03-15 | 2014 | G. Germano Group President, Global Innovative Pharma Business | 1,150,000 | 0 | 1,813,518 | 1,355,000 | 630,593 | 9,555,852 |
| 2016-03-15 | 2014 | J. Young Group President, Global Established Pharma Business | 1,040,000 | 0 | 1,813,518 | 1,260,000 | 326,498 | 7,250,187 |
| 2016-03-15 | 2015 | J. Young Group President, Global Established Pharma Business | 1,085,000 | 0 | 603,492 | 2,100,000 | 377,537 | 5,918,925 |
| 2016-03-15 | 2013 | G. Germano Group President, Global Innovative Pharma Business | 926,250 | 0 | 1,529,600 | 1,075,000 | 173,174 | 5,254,047 |
| 2016-03-15 | 2013 | M. Dolsten President, Worldwide Research and Development | 1,148,750 | 0 | 1,835,542 | 1,340,000 | 164,512 | 6,453,404 |
| 2016-03-15 | 2014 | M. Dolsten President, Worldwide Research and Development | 1,177,500 | 0 | 1,863,860 | 1,300,000 | 156,180 | 7,275,054 |
| 2016-03-15 | 2013 | I. Read Chairman and Chief Executive Officer | 1,776,250 | 0 | 6,016,528 | 3,400,000 | 476,300 | 18,947,747 |
| 2016-03-15 | 2015 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,293,750 | 0 | 603,492 | 2,341,000 | 169,132 | 6,670,174 |
| 2016-03-15 | 2015 | M. Dolsten President, Worldwide Research and Development | 1,207,500 | 0 | 603,492 | 1,850,000 | 185,813 | 6,057,866 |
| 2016-03-15 | 2013 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,243,750 | 0 | 1,937,522 | 1,650,000 | 235,655 | 7,124,330 |
| 2016-03-15 | 2014 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,268,750 | 0 | 2,140,974 | 1,300,000 | 217,488 | 8,482,813 |
| 2016-03-15 | 2013 | J. Young Group President, Global Established Pharma Business | 810,075 | 0 | 1,121,732 | 1,075,000 | 287,603 | 5,296,346 |
| 2016-03-15 | 2015 | G. Germano Group President, Global Innovative Pharma Business | 1,168,750 | 0 | 603,492 | 1,850,000 | 187,621 | 6,782,720 |
| 2016-03-15 | 2014 | I. Read Chairman and Chief Executive Officer | 1,815,000 | 0 | 6,447,998 | 3,000,000 | 391,828 | 23,283,048 |
| 2016-03-15 | 2015 | I. Read Chairman and Chief Executive Officer | 1,858,750 | 0 | 2,011,628 | 4,300,000 | 388,036 | 17,987,962 |
| 2015-03-12 | 2012 | M. Dolsten President, Worldwide Research and | 1,122,500 | 0 | 0 | 0 | 96,752 | 6,839,181 |
| 2015-03-12 | 2013 | M. Dolsten President, Worldwide Research and | 1,148,750 | 0 | 0 | 0 | 164,512 | 6,453,404 |
| 2015-03-12 | 2014 | M. Dolsten President, Worldwide Research and | 1,177,500 | 0 | 0 | 0 | 156,180 | 7,275,054 |
| 2015-03-12 | 2012 | F. D’Amelio EVP, Business Operations | 1,218,750 | 0 | 0 | 0 | 173,245 | 7,387,091 |
| 2015-03-12 | 2014 | J. Young Group President, | 1,040,000 | 0 | 0 | 0 | 326,498 | 7,250,187 |
| 2015-03-12 | 2013 | J. Young Group President, | 810,075 | 0 | 0 | 0 | 287,603 | 5,296,346 |
| 2015-03-12 | 2014 | I. Read Chairman and Chief Executive Officer | 1,815,000 | 0 | 0 | 0 | 391,828 | 23,283,048 |
| 2015-03-12 | 2013 | I. Read Chairman and Chief Executive Officer | 1,776,250 | 0 | 0 | 0 | 476,300 | 18,947,747 |
| 2015-03-12 | 2012 | I. Read Chairman and Chief Executive Officer | 1,737,500 | 0 | 0 | 0 | 409,892 | 25,634,136 |
| 2015-03-12 | 2014 | F. D’Amelio EVP, Business Operations | 1,268,750 | 0 | 0 | 0 | 217,488 | 8,482,813 |
| 2015-03-12 | 2013 | F. D’Amelio EVP, Business Operations | 1,243,750 | 0 | 0 | 0 | 235,655 | 7,124,330 |
| 2015-03-12 | 2012 | G. Germano Group President, Global Innovative | 893,750 | 0 | 0 | 0 | 121,728 | 7,312,405 |
| 2015-03-12 | 2013 | G. Germano Group President, Global Innovative | 926,250 | 0 | 0 | 0 | 173,174 | 5,254,047 |
| 2015-03-12 | 2014 | G. Germano Group President, Global Innovative | 1,150,000 | 0 | 0 | 0 | 630,593 | 9,555,852 |
| 2014-03-13 | 2012 | M. Dolsten President, Worldwide Research and | 1,122,500 | 0 | 0 | 0 | 96,752 | 6,839,181 |
| 2014-03-13 | 2011 | M. Dolsten President, Worldwide Research and | 1,100,000 | 0 | 0 | 0 | 90,801 | 6,976,735 |
| 2014-03-13 | 2013 | G. Germano President and General Manager, | 926,250 | 0 | 0 | 0 | 173,174 | 5,254,047 |
| 2014-03-13 | 2012 | G. Germano President and General Manager, | 893,750 | 0 | 0 | 0 | 121,728 | 7,312,405 |
| 2014-03-13 | 2011 | G. Germano President and General Manager, | 875,000 | 0 | 0 | 0 | 50,214 | 6,402,331 |
| 2014-03-13 | 2013 | O. Brandicourt | 812,083 | 0 | 0 | 0 | 3,483,941 | 8,103,381 |
| 2014-03-13 | 2011 | A. W. Schulman Former EVP and General Counsel; Business | 900,000 | 0 | 0 | 0 | 94,172 | 5,764,662 |
| 2014-03-13 | 2013 | A. W. Schulman Former EVP and General Counsel; Business | 952,750 | 0 | 0 | 0 | 110,482 | 5,120,741 |
| 2014-03-13 | 2012 | A. W. Schulman Former EVP and General Counsel; Business | 918,750 | 0 | 0 | 0 | 87,411 | 5,573,218 |
| 2014-03-13 | 2013 | J. Young | 810,075 | 0 | 0 | 0 | 192,312 | 5,201,055 |
| 2014-03-13 | 2013 | I. Read Chairman and Chief Executive Officer | 1,776,250 | 0 | 0 | 0 | 476,300 | 18,947,747 |
| 2014-03-13 | 2012 | I. Read Chairman and Chief Executive Officer | 1,737,500 | 0 | 0 | 0 | 409,892 | 25,634,136 |
| 2014-03-13 | 2011 | I. Read Chairman and Chief Executive Officer | 1,700,000 | 0 | 0 | 0 | 319,288 | 25,013,348 |
| 2014-03-13 | 2013 | F. D’Amelio EVP, Business Operations | 1,243,750 | 0 | 0 | 0 | 235,655 | 7,124,330 |
| 2014-03-13 | 2012 | F. D’Amelio EVP, Business Operations | 1,218,750 | 0 | 0 | 0 | 173,245 | 7,387,091 |
| 2014-03-13 | 2011 | F. D’Amelio EVP, Business Operations | 1,200,000 | 0 | 0 | 0 | 187,425 | 7,690,743 |
| 2014-03-13 | 2013 | M. Dolsten President, Worldwide Research and | 1,148,750 | 0 | 0 | 0 | 164,512 | 6,453,404 |
| 2013-03-14 | 2012 | A. W. Schulman EVP and General | 918,750 | 0 | 1,387,476 | 1,410,000 | 87,411 | 5,573,218 |
| 2013-03-14 | 2012 | I. Read Chairman and Chief Executive Officer | 1,737,500 | 0 | 6,441,784 | 3,400,000 | 409,892 | 25,634,136 |
| 2013-03-14 | 2011 | I. Read Chairman and Chief Executive Officer | 1,700,000 | 0 | 5,684,218 | 3,500,000 | 319,288 | 25,013,348 |
| 2013-03-14 | 2010 | I. Read Chairman and Chief Executive Officer | 1,199,000 | 0 | 2,673,276 | 1,500,000 | 209,652 | 17,396,112 |
| 2013-03-14 | 2012 | F. D’Amelio EVP, Business Operations | 1,218,750 | 0 | 1,783,890 | 1,718,000 | 173,245 | 7,387,091 |
| 2013-03-14 | 2012 | G. Germano President and General Manager, | 893,750 | 0 | 1,387,476 | 1,203,000 | 121,728 | 7,312,405 |
| 2013-03-14 | 2011 | G. Germano President and General Manager, | 875,000 | 0 | 1,591,598 | 1,135,000 | 50,214 | 6,402,331 |
| 2013-03-14 | 2011 | A. W. Schulman EVP and General | 900,000 | 0 | 1,705,287 | 1,190,000 | 94,172 | 5,764,662 |
| 2013-03-14 | 2010 | G. Germano President and General Manager, | 818,000 | 750,000 | 1,130,414 | 930,000 | 25,648 | 4,812,107 |
| 2013-03-14 | 2011 | F. D’Amelio EVP, Business Operations | 1,200,000 | 0 | 2,046,310 | 1,440,000 | 187,425 | 7,690,743 |
| 2013-03-14 | 2010 | F. D’Amelio EVP, Business Operations | 1,090,000 | 0 | 2,673,276 | 1,175,000 | 193,823 | 6,500,073 |
| 2013-03-14 | 2012 | M. Dolsten President, Worldwide Research and | 1,122,500 | 0 | 1,783,890 | 1,395,000 | 96,752 | 6,839,181 |
| 2013-03-14 | 2011 | M. Dolsten President, Worldwide Research and | 1,100,000 | 0 | 2,046,310 | 1,490,000 | 90,801 | 6,976,735 |
| 2013-03-14 | 2010 | M. Dolsten President, Worldwide Research and | 900,000 | 1,050,000 | 1,985,860 | 1,000,000 | 61,004 | 5,903,686 |
| 2012-03-15 | 2011 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,200,000 | 0 | 2,046,310 | 1,440,000 | 187,425 | 7,690,743 |
| 2012-03-15 | 2009 | I. Read Chairman and Chief Executive Officer* | 1,139,500 | 500,000 | 2,854,366 | 1,657,000 | 226,643 | 9,447,626 |
| 2012-03-15 | 2010 | I. Read Chairman and Chief Executive Officer* | 1,199,000 | 0 | 2,673,276 | 1,500,000 | 209,652 | 17,396,112 |
| 2012-03-15 | 2011 | I. Read Chairman and Chief Executive Officer* | 1,700,000 | 0 | 5,684,218 | 3,500,000 | 319,288 | 25,013,348 |
| 2012-03-15 | 2011 | A. W. Schulman EVP, General Counsel, and President & GM, Nutrition | 900,000 | 0 | 1,705,287 | 1,190,000 | 94,172 | 5,764,662 |
| 2012-03-15 | 2010 | M. Dolsten President, Worldwide Research and Development | 900,000 | 1,050,000 | 1,985,860 | 1,000,000 | 61,004 | 5,903,686 |
| 2012-03-15 | 2011 | M. Dolsten President, Worldwide Research and Development | 1,100,000 | 0 | 2,046,310 | 1,490,000 | 90,801 | 6,976,735 |
| 2012-03-15 | 2009 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,060,000 | 600,000 | 2,904,366 | 1,420,000 | 205,287 | 7,859,559 |
| 2012-03-15 | 2010 | F. D’Amelio EVP, Business Operations and Chief Financial Officer | 1,090,000 | 0 | 2,673,276 | 1,175,000 | 193,823 | 6,500,073 |
| 2012-03-15 | 2011 | D. Simmons President and GM, Emerging Markets and Established Products | 850,000 | 0 | 1,591,598 | 1,135,000 | 132,180 | 5,976,891 |
| 2011-03-22 | 2010 | 2010 SUMMARY COMPENSATION TABLE | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-03-16 | 2009 | 2009 Summary Compensation Table Name and Principal Position (a) | 2,009 | 2,009 | 2,009 | 0 | 0 | 6,027 |
| 2010-03-16 | 2009 | F. Lewis-Hall Chief Medical Officer | 503,030 | 1,626,700 | 1,000,003 | 0 | 0 | 3,129,733 |
| 2009-03-13 | 2008 | 2008 Summary Compensation Table Name and Principal Position (a) | 2,008 | 2,008 | 0 | 0 | 0 | 4,016 |
| 2009-03-13 | 2008 | C. Goodman President, Biotherapeutics & Bioinnovation Center | 736,250 | 1,700,000 | 778,905 | 0 | 0 | 3,215,155 |
| 2008-03-14 | 2007 | A. Levin Former | 687,943 | 486,750 | 36,998 | 0 | 0 | 1,211,691 |
| 2008-03-14 | 2007 | J. Kindler Chairman and | 1,462,500 | 3,100,000 | 1,162,835 | 0 | 0 | 5,725,335 |
| 2008-03-14 | 2006 | J. Kindler Chairman and | 1,103,883 | 3,300,000 | 2,736,265 | 0 | 0 | 7,140,148 |
| 2008-03-14 | 2007 | F. D’Amelio Chief Financial | 320,625 | 4,040,000 | 907,717 | 0 | 0 | 5,268,342 |
| 2008-03-14 | 2006 | A. Levin Former | 784,575 | 580,600 | 2,026,454 | 0 | 0 | 3,391,629 |
| 2008-03-14 | 2006 | F. D’Amelio Chief Financial | 0 | 0 | 0 | 0 | 0 | 0 |
| 2008-03-14 | 2007 | D. Shedlarz Former Vice Chairman | 1,056,875 | 951,200 | 62,339 | 0 | 0 | 2,070,414 |
| 2008-03-14 | 2006 | D. Shedlarz Former Vice Chairman | 1,008,225 | 1,263,400 | 3,181,563 | 0 | 0 | 5,453,188 |
| 2008-03-14 | 2007 | I. Read President, Worldwide | 944,083 | 990,000 | 190,134 | 0 | 0 | 2,124,217 |
| 2008-03-14 | 2006 | I. Read President, Worldwide | 813,450 | 667,200 | 1,651,580 | 0 | 0 | 3,132,230 |
| 2008-03-14 | 2007 | M. Mackay President, | 702,159 | 645,000 | 166,291 | 0 | 0 | 1,513,450 |
| 2008-03-14 | 2006 | J. LaMattina Former President, | 873,275 | 718,300 | 2,451,516 | 0 | 0 | 4,043,091 |
| 2008-03-14 | 2007 | J. LaMattina Former President, | 911,300 | 683,500 | 247,364 | 0 | 0 | 1,842,164 |
| 2008-03-14 | 2006 | M. Mackay President, | 0 | 0 | 0 | 0 | 0 | 0 |
| 2006-03-16 | 2004 | Mr. Kindler Vice Chairman and General Counsel | 887,300 | 869,600 | 792,561 | 0 | 80,496 | 2,629,957 |
| 2006-03-16 | 2004 | Vice Chairman and President, Pfizer Human Health | 1,158,300 | 1,274,100 | 2,326,218 | 0 | 117,751 | 4,876,369 |
| 2006-03-16 | 2005 | Vice Chairman and President, Pfizer Human Health | 1,176,200 | 1,535,600 | 0 | 0 | 110,263 | 2,822,063 |
| 2006-03-16 | 2003 | Dr. McKinnell Chairman and CEO | 2,042,700 | 4,607,400 | 0 | 0 | 249,390 | 6,899,490 |
| 2006-03-16 | 2004 | Dr. McKinnell Chairman and CEO | 2,224,900 | 3,986,300 | 4,292,181 | 0 | 307,454 | 10,810,835 |
| 2006-03-16 | 2003 | Senior V.P.; President, Pfizer Global Research and Development | 677,250 | 596,900 | 199,303 | 0 | 50,353 | 1,523,806 |
| 2006-03-16 | 2004 | Senior V.P.; President, Pfizer Global Research and Development | 820,000 | 705,200 | 1,024,154 | 0 | 63,760 | 2,613,114 |
| 2006-03-16 | 2003 | Mr. Shedlarz Vice Chairman | 889,133 | 1,043,100 | 260,866 | 0 | 79,922 | 2,273,021 |
| 2006-03-16 | 2004 | Mr. Shedlarz Vice Chairman | 966,500 | 1,005,200 | 1,873,326 | 0 | 90,432 | 3,935,458 |
| 2006-03-16 | 2005 | Mr. Shedlarz Vice Chairman | 983,100 | 1,088,000 | 0 | 0 | 89,473 | 2,160,573 |
| 2006-03-16 | 2003 | Vice Chairman and President, Pfizer Human Health | 1,086,700 | 1,434,400 | 326,840 | 0 | 103,631 | 2,951,571 |
| 2006-03-16 | 2005 | Senior V.P.; President, Pfizer Global Research and Development | 837,500 | 787,300 | 0 | 0 | 69,421 | 1,694,221 |
| 2006-03-16 | 2003 | Mr. Kindler Vice Chairman and General Counsel | 827,900 | 901,500 | 248,989 | 0 | 68,962 | 2,047,351 |
| 2006-03-16 | 2005 | Mr. Kindler Vice Chairman and General Counsel | 902,200 | 1,000,000 | 0 | 0 | 79,731 | 1,981,931 |
| 2006-03-16 | 2005 | Dr. McKinnell Chairman and CEO | 2,270,500 | 3,700,000 | 0 | 0 | 281,556 | 6,252,056 |
| 2005-03-09 | 2003 | Senior V.P.; President, Pfizer Global Research and Development | 677,250 | 596,900 | 199,303 | 0 | 50,353 | 1,523,806 |
| 2005-03-09 | 2004 | Mr. Kindler Vice Chairman and General Counsel | 887,300 | 869,600 | 792,561 | 0 | 80,496 | 2,629,957 |
| 2005-03-09 | 2002 | Mr. Shedlarz Vice Chairman | 834,000 | 886,900 | 0 | 0 | 70,369 | 1,791,269 |
| 2005-03-09 | 2004 | Dr. McKinnell Chairman and CEO | 2,224,900 | 3,986,300 | 4,292,181 | 0 | 307,454 | 10,810,835 |
| 2005-03-09 | 2003 | Dr. McKinnell Chairman and CEO | 2,042,700 | 4,607,400 | 0 | 0 | 249,390 | 6,899,490 |
| 2005-03-09 | 2002 | Dr. McKinnell Chairman and CEO | 1,809,900 | 3,499,300 | 0 | 0 | 205,915 | 5,515,115 |
| 2005-03-09 | 2002 | Senior V.P.; President, Pfizer Global Research and Development | 630,800 | 441,700 | 508,500 | 0 | 49,452 | 1,630,452 |
| 2005-03-09 | 2003 | Mr. Shedlarz Vice Chairman | 889,133 | 1,043,100 | 260,866 | 0 | 79,922 | 2,273,021 |
| 2005-03-09 | 2004 | Mr. Shedlarz Vice Chairman | 966,500 | 1,005,200 | 1,873,326 | 0 | 90,432 | 3,935,458 |
| 2005-03-09 | 2002 | Vice Chairman and President, Pfizer Human Health | 984,100 | 1,240,200 | 0 | 0 | 90,871 | 2,315,171 |
| 2005-03-09 | 2003 | Vice Chairman and President, Pfizer Human Health | 1,086,700 | 1,434,400 | 326,840 | 0 | 103,631 | 2,951,571 |
| 2005-03-09 | 2004 | Vice Chairman and President, Pfizer Human Health | 1,158,300 | 1,274,100 | 2,326,218 | 0 | 117,751 | 4,876,369 |
| 2005-03-09 | 2004 | Senior V.P.; President, Pfizer Global Research and Development | 820,000 | 705,200 | 1,024,154 | 0 | 63,760 | 2,613,114 |
| 2005-03-09 | 2002 | Mr. Kindler Vice Chairman and General Counsel | 725,000 | 704,600 | 798,000 | 0 | 621,934 | 2,849,534 |
| 2005-03-09 | 2003 | Mr. Kindler Vice Chairman and General Counsel | 827,900 | 901,500 | 248,989 | 0 | 68,962 | 2,047,351 |
| 2004-03-12 | 2001 | Mr. Kindler Senior V.P. and General Counsel | 0 | 0 | 0 | 0 | 89,354 | 89,354 |
| 2004-03-12 | 2001 | Executive V.P.; President, Pfizer Global Pharmaceuticals | 854,625 | 1,043,400 | 0 | 0 | 79,922 | 1,977,947 |
| 2004-03-12 | 2002 | Mr. Kindler Senior V.P. and General Counsel | 725,000 | 704,600 | 798,000 | 0 | 0 | 2,227,600 |
| 2004-03-12 | 2003 | Mr. Kindler Senior V.P. and General Counsel | 827,900 | 901,500 | 248,989 | 0 | 621,934 | 2,600,323 |
| 2004-03-12 | 2003 | Dr. McKinnell Chairman and CEO | 2,042,700 | 4,607,400 | 0 | 0 | 205,915 | 6,856,015 |
| 2004-03-12 | 2001 | Dr. Corr Senior V.P., Science and Technology | 630,000 | 530,000 | 0 | 0 | 0 | 1,160,000 |
| 2004-03-12 | 2002 | Dr. Corr Senior V.P., Science and Technology | 705,700 | 530,000 | 0 | 0 | 42,076 | 1,277,776 |
| 2004-03-12 | 2001 | Mr. Shedlarz Executive V.P. and CFO | 772,800 | 736,900 | 0 | 0 | 68,962 | 1,578,662 |
| 2004-03-12 | 2002 | Mr. Shedlarz Executive V.P. and CFO | 834,000 | 886,900 | 0 | 0 | 59,860 | 1,780,760 |
| 2004-03-12 | 2002 | Executive V.P.; President, Pfizer Global Pharmaceuticals | 984,100 | 1,240,200 | 0 | 0 | 63,397 | 2,287,697 |
| 2004-03-12 | 2001 | Dr. McKinnell Chairman and CEO | 1,516,667 | 2,780,800 | 0 | 0 | 0 | 4,297,467 |
| 2004-03-12 | 2002 | Dr. McKinnell Chairman and CEO | 1,809,900 | 3,499,300 | 0 | 0 | 117,743 | 5,426,943 |
| 2004-03-12 | 2003 | Executive V.P.; President, Pfizer Global Pharmaceuticals | 1,086,700 | 1,434,400 | 326,840 | 0 | 90,871 | 2,938,811 |
| 2004-03-12 | 2003 | Mr. Shedlarz Executive V.P. and CFO | 889,133 | 1,043,100 | 260,866 | 0 | 70,369 | 2,263,468 |
| 2004-03-12 | 2003 | Dr. Corr Senior V.P., Science and Technology | 806,000 | 815,000 | 242,403 | 0 | 114,625 | 1,978,028 |
| 2003-03-17 | 2001 | Mr. Shedlarz Executive V.P. and CFO | 772,800 | 736,900 | 0 | 0 | 59,860 | 1,569,560 |
| 2003-03-17 | 2001 | Ms. Katen Executive V.P.; President- Pfizer Pharmaceuticals | 854,625 | 1,043,400 | 0 | 0 | 63,397 | 1,961,422 |
| 2003-03-17 | 2000 | Mr. Kindler Senior V.P. and General Counsel | 0 | 0 | 0 | 0 | 0 | 0 |
| 2003-03-17 | 2002 | Dr. Corr Senior V.P., Science and Technology | 705,700 | 530,000 | 0 | 0 | 114,625 | 1,350,325 |
| 2003-03-17 | 2001 | Dr. Corr Senior V.P., Science and Technology | 630,000 | 530,000 | 0 | 0 | 42,076 | 1,202,076 |
| 2003-03-17 | 2000 | Dr. Corr Senior V.P., Science and Technology | 575,000 | 530,000 | 0 | 0 | 28,247 | 1,133,247 |
| 2003-03-17 | 2002 | Dr. Niblack Former Vice Chairman* | 686,067 | 708,500 | 0 | 0 | 78,301 | 1,472,868 |
| 2003-03-17 | 2001 | Dr. Niblack Former Vice Chairman* | 944,600 | 1,062,700 | 0 | 0 | 75,080 | 2,082,380 |
| 2003-03-17 | 2000 | Dr. Niblack Former Vice Chairman* | 832,500 | 932,400 | 1,096,949 | 0 | 69,128 | 2,930,977 |
| 2003-03-17 | 2002 | Dr. McKinnell Chairman and CEO | 1,809,900 | 3,499,300 | 0 | 0 | 205,915 | 5,515,115 |
| 2003-03-17 | 2001 | Dr. McKinnell Chairman and CEO | 1,516,667 | 2,780,800 | 0 | 0 | 117,743 | 4,415,210 |
| 2003-03-17 | 2002 | Ms. Katen Executive V.P.; President- Pfizer Pharmaceuticals | 984,100 | 1,240,200 | 0 | 0 | 90,871 | 2,315,171 |
| 2003-03-17 | 2000 | Dr. McKinnell Chairman and CEO | 984,100 | 1,426,900 | 1,408,826 | 0 | 83,084 | 3,902,910 |
| 2003-03-17 | 2001 | Mr. Kindler Senior V.P. and General Counsel | 0 | 0 | 0 | 0 | 0 | 0 |
| 2003-03-17 | 2002 | Mr. Kindler Senior V.P. and General Counsel | 725,000 | 704,600 | 798,000 | 0 | 621,934 | 2,849,534 |
| 2003-03-17 | 2000 | Mr. Shedlarz Executive V.P. and CFO | 695,100 | 723,700 | 763,562 | 0 | 53,508 | 2,235,870 |
| 2003-03-17 | 2002 | Mr. Shedlarz Executive V.P. and CFO | 834,000 | 886,900 | 0 | 0 | 70,369 | 1,791,269 |
| 2003-03-17 | 2000 | Ms. Katen Executive V.P.; President- Pfizer Pharmaceuticals | 698,800 | 730,300 | 688,282 | 0 | 53,772 | 2,171,154 |
| 2002-03-14 | 1999 | Mr. Steere Former Chairman** | 1,436,300 | 2,872,600 | 0 | 0 | 167,828 | 4,476,728 |
| 2002-03-14 | 2001 | Dr. Niblack Vice Chairman | 944,600 | 1,062,700 | 0 | 0 | 75,080 | 2,082,380 |
| 2002-03-14 | 1999 | Mr. Shedlarz Executive V.P. and CFO | 625,800 | 642,600 | 65,453 | 0 | 47,556 | 1,381,409 |
| 2002-03-14 | 2001 | Mr. Steere Former Chairman** | 808,000 | 1,616,000 | 0 | 0 | 549,440 | 2,973,440 |
| 2002-03-14 | 1999 | C.L. Clemente Executive V.P.- Corporate Affairs; Secretary and Corporate Counsel | 625,800 | 654,000 | 0 | 0 | 43,320 | 1,323,120 |
| 2002-03-14 | 2000 | Dr. Niblack Vice Chairman | 832,500 | 932,400 | 1,096,949 | 0 | 69,128 | 2,930,977 |
| 2002-03-14 | 2000 | C.L. Clemente Executive V.P.- Corporate Affairs; Secretary and Corporate Counsel | 651,500 | 680,900 | 645,264 | 0 | 45,420 | 2,023,084 |
| 2002-03-14 | 2001 | C.L. Clemente Executive V.P.- Corporate Affairs; Secretary and Corporate Counsel | 679,500 | 680,900 | 0 | 0 | 54,416 | 1,414,816 |
| 2002-03-14 | 2000 | Mr. Shedlarz Executive V.P. and CFO | 695,100 | 723,700 | 763,562 | 0 | 53,508 | 2,235,870 |
| 2002-03-14 | 2001 | Mr. Shedlarz Executive V.P. and CFO | 772,800 | 736,900 | 0 | 0 | 59,860 | 1,569,560 |
| 2002-03-14 | 1999 | Ms. Katen* Executive V.P.; President-Pfizer Pharmaceuticals Group and President-U.S. Pharmaceuticals | 625,800 | 645,500 | 130,906 | 0 | 45,304 | 1,447,510 |
| 2002-03-14 | 2000 | Ms. Katen* Executive V.P.; President-Pfizer Pharmaceuticals Group and President-U.S. Pharmaceuticals | 698,800 | 730,300 | 688,282 | 0 | 53,772 | 2,171,154 |
| 2002-03-14 | 2001 | Dr. McKinnell* Chairman and CEO | 1,516,667 | 2,780,800 | 0 | 0 | 117,743 | 4,415,210 |
| 2002-03-14 | 2000 | Dr. McKinnell* Chairman and CEO | 984,100 | 1,426,900 | 1,408,826 | 0 | 83,084 | 3,902,910 |
| 2002-03-14 | 1999 | Dr. McKinnell* Chairman and CEO | 869,800 | 1,093,000 | 2,003,125 | 0 | 76,796 | 4,042,721 |
| 2002-03-14 | 2001 | Ms. Katen* Executive V.P.; President-Pfizer Pharmaceuticals Group and President-U.S. Pharmaceuticals | 854,625 | 1,043,400 | 0 | 0 | 63,397 | 1,961,422 |
| 2002-03-14 | 1999 | Dr. Niblack Vice Chairman | 799,700 | 895,700 | 1,802,813 | 0 | 66,404 | 3,564,617 |
| 2002-03-14 | 2000 | Mr. Steere Former Chairman** | 1,616,000 | 3,232,000 | 2,688,600 | 0 | 179,544 | 7,716,144 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
